Department of Urology, University of California, Davis Medical Center, Sacramento, California 95817, USA.
Urology. 2010 Dec;76(6):1409-13. doi: 10.1016/j.urology.2010.03.024.
We sought to evaluate the impact of socioeconomic status (SES) on the likelihood of undergoing radical prostatectomy (RP) or external beam radiation therapy (XRT) and the ensuing effect on cancer-specific survival (CSS) after treatment for men with low-risk prostate cancer.
Using the California Cancer Registry database, we identified 123,953 men diagnosed with localized, Gleason ≤7 prostate cancer from 1996 to 2005. Patients were separated into quintiles based on socioeconomic status and were stratified by race, age, year of diagnosis, and treatment. Logistic regression and Kaplan-Meier analyses were used to determine the likelihood of undergoing RP or XRT and cancer-specific survival.
In the final cohort, 39,234 patients (31.7%) and 42,431 patients (34.3%) underwent RP and XRT as initial therapy. Men of lower SES were less likely to undergo RP or XRT. Men undergoing RP in the lowest SES were twice as likely to die of prostate cancer (HR 1.99, 95% CI 1.28-3.09, P = .002) than men in the highest SES. This difference was even more profound when adjusted for race (HR 2.20, 95% CI 1.38-3.50, P = .001). Similarly, men in the lowest SES who underwent XRT were also approximately twice as likely to die of prostate cancer (HR 2.24, 95% CI 1.71-2.94, P <.001) than men of the highest SES, regardless of race.
Men of lower SES are less likely to undergo RP or XRT for the management of localized prostate cancer. After RP or XRT, men of lower SES have a decreased cancer-specific survival compared with men of higher SES.
我们旨在评估社会经济地位(SES)对低危前列腺癌患者接受根治性前列腺切除术(RP)或外束放射治疗(XRT)的可能性的影响,以及治疗后对癌症特异性生存(CSS)的影响。
使用加利福尼亚癌症登记处数据库,我们从 1996 年至 2005 年确定了 123953 名诊断为局限性、Gleason ≤7 前列腺癌的男性患者。患者根据 SES 分为五组,并按种族、年龄、诊断年份和治疗进行分层。采用逻辑回归和 Kaplan-Meier 分析来确定接受 RP 或 XRT 的可能性以及癌症特异性生存率。
在最终队列中,39234 名患者(31.7%)和 42431 名患者(34.3%)接受 RP 和 XRT 作为初始治疗。社会经济地位较低的男性接受 RP 或 XRT 的可能性较小。社会经济地位最低的 RP 患者死于前列腺癌的风险是社会经济地位最高的患者的两倍(HR 1.99,95%CI 1.28-3.09,P =.002)。当按种族进行调整时,这种差异更为明显(HR 2.20,95%CI 1.38-3.50,P =.001)。同样,接受 XRT 的社会经济地位最低的男性死于前列腺癌的风险也几乎是社会经济地位最高的男性的两倍(HR 2.24,95%CI 1.71-2.94,P <.001),无论种族如何。
社会经济地位较低的男性更不可能接受 RP 或 XRT 治疗局限性前列腺癌。接受 RP 或 XRT 治疗后,社会经济地位较低的男性与社会经济地位较高的男性相比,癌症特异性生存率降低。